- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Evan Diamond
Insight 12 results
Client Alert
April 7, 2021
“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?
Client Alert
Client Alert
February 12, 2021
GSK v. Teva and Induced Infringement by AB-Rated Generics: Where are we now?
Article · Source: Law360
February 3, 2021
Challenging Therapeutics IP After Fed. Circ. Drink Can Ruling
Client Alert
January 7, 2021
The Federal Circuit’s Ball Metal Decision Raises Important Considerations for Pharma and Biologics Patents
Client Alert
April 3, 2020
D.C. Circuit Concludes that Serial Periods of Exclusivity May Be Available Under the Orphan Drug Act
Article · Source: Intellectual Property & Technology Law Journal
February 1, 2020
Federal Circuit Continues Trend of Finding Diagnostic Inventions to Be Patent-Ineligible
Article · Source: Law360
August 20, 2019
Fed. Circ.'s Arduous Legal Landscape For Diagnostic Patents
Client Alert
August 13, 2019
Federal Circuit Continues Trend of Finding Diagnostic Inventions to Be Patent-Ineligible
Article · Source: Bloomberg Law
April 29, 2019
Big Pharma Should Watch SCOTUS After Circuit Court Finds New Drug Uses Patentable
Article · Source: Law360
January 17, 2019
Takeaways From Fed. Circ. Hatch-Waxman IPR Case